Leukemias, lymphomas, and other hematologic cancers:
Indications for: EVOMELA
High-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
Give prophylactic antiemetics. Give by IV infusion over 30mins. 100mg/m2 daily for 2 consecutive days (Days -3 and -2) prior to transplantation (Day 0). If patient weighs >130% of their ideal body weight, use adjusted ideal body weight.
Severe bone marrow suppression. Hypersensitivity. Leukemogenicity.
Bone marrow suppression. Monitor CBCs, provide supportive care for infections, anemia, thrombocytopenia until adequate recovery. GI toxicity; provide supportive care. Monitor LFTs. Renal impairment. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or for 3 months (males w. female partners) after the last dose. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).
Caution with cyclosporine, BCNU.
Decreased neutrophil, WBC, lymphocyte, and platelet counts, diarrhea, nausea, fatigue, hypokalemia, anemia, vomiting; mucositis, hypersensitivity reactions, hepatic disorders, secondary malignancies, infertility.
Generic Drug Availability:
Single-dose vial (20mL)—1